Sysmex Corporation (HQ: Kobe, Japan; President and CEO: Hisashi Ietsugu) has decided to acquire a site for the production of a new instrument factory in the city of Kakogawa, Hyogo Prefecture. The new factory will greatly increase the Company’s production capacity in response to growing global demand for in vitro diagnostic (IVD) testing instruments.
The hematology field has been Sysmex’s core business since its founding, and the Company now has the leading global share of this market. We are also expanding our operations in non-hematology fields*, and provide customers in more than 170 countries with instruments, reagents and support services.
Sysmex manufactures its instruments in Japan, leveraging its advanced "made in Japan" expertise, and delivers those instruments to customers around the world. In line with a growing market share and expanding portfolio of products, each year the Company has seen a steady increase in the products it provides to customers globally. We have augmented our factories and renovated our manufacturing systems to keep pace with this growth and to provide a stable supply of products.
The external environment is characterized by increased investment in healthcare infrastructure in emerging markets, in tandem with their robust economic growth. In addition, healthcare needs in advanced countries are growing more diverse as their populations age. As a result of these changes, we anticipate an ongoing expansion of the global IVD testing market.
To meet this expected increase in global demand for IVD testing instruments, Sysmex has decided to acquire a site for the construction of a new instrument production factory in the city of Kakogawa, to substantially boost its production capacity. In addition to continuing operations at the existing instrument factory, the new facility will become a core instrument production factory for the Sysmex Group, augmenting production capacity substantially.
The city of Kakogawa affords good access to the Company’s existing instrument production factory, as well as the R&D base at Technopark (Nishi-ku, Kobe). Building the new factory will maximize the Company’s leverage of its management resources and create a manufacturing structure that will allow more efficient production of higher-quality products. We will develop more detailed plans for the new factory going forward.
In the future, as well, Sysmex aims to contribute to human health by providing a stable supply of high-quality, high-value-added products to customers around the world.
|Overview of Site to Be Acquired
||262-11 Mizuashi-aza Kobashi, Noguchi-cho, Kakogawa, Hyogo Prefecture
|2. Site Area:
||Approximately 30,000 square meters
|3. Acquisition date:
||December 28, 2012 (scheduled)
* Non-hematology: in vitro diagnostics fields excluding hematology but including hemostasis, immunochemistry, urinalysis, clinical chemistry and others
- Information contained in the press release is current as of the date of the announcement,
but may be subject to change without prior notice.